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Abstract
Creation of a nuclear export signal (NES) motif and loss of
tryptophans (W) 288 and 290 (or 290 only) at the COOH
terminus of nucleophosmin (NPM) are both crucial for NPM
aberrant cytoplasmic accumulation in acute myelogenous
leukemia (AML) carrying NPM1 mutations. Hereby, we
clarify how these COOH-terminal alterations functionally
cooperate to delocalize NPM to the cytoplasm. Using a
Rev(1.4)-based shuttling assay, we measured the nuclear
export efficiency of six different COOH-terminal NES motifs
identified in NPM mutants and found significant strength
variability, the strongest NES motifs being associated with
NPM mutants retaining W288. When artificially coupled
with a weak NES, W288-retaining NPM mutants are not
exported efficiently into cytoplasm because the force (W288)
driving the mutants toward the nucleolus overwhelms the
force (NES) exporting the mutants into cytoplasm. We then
used this functional assay to study the physiologic NH2-
terminal NES motifs of wild-type NPM and found that they
are weak, which explains the prominent nucleolar localiza-
tion of wild-type NPM. Thus, the opposing balance of forces
(tryptophans and NES) seems to determine the subcellular
localization of NPM. The fact that W288-retaining mutants
always combine with the strongest NES reveals mutational
selective pressure toward efficient export into cytoplasm,
pointing to this event as critical for leukemogenesis. [Cancer
Res 2007;67(13):6230–7]
Introduction
Macromolecule transport into and out of the nucleus through
the nuclear pore complex is essential for regulating cell functions
(1) and, in fact, nucleocytoplasmic transport is altered in a variety
of tumors (2). In acute leukemias, NUP214 and NUP98 gene
translocations cause abnormal protein traffic through nuclear
pores (3, 4). However, the most remarkable example of disrupted
nucleocytoplasmic transport in leukemias involves nucleophosmin
(NPM; ref. 5), a multifunctional shuttling phosphoprotein (6)
residing mainly in the nucleolus (7). Indeed, f30% of de novo
acute myelogenous leukemia (AML) exhibiting distinctive clinico-
pathologic (5) and prognostic (8–11) features carry NPM1 gene
mutations that cause aberrant NPM accumulation in leukemic cell
cytoplasm (5, 12). For this reason, we named this leukemia
‘‘cytoplasmic positive (NPMc+) AML’’ (5).
In NPMc+ AML, NPM1 mutations alter tryptophans 288 and 290
(or 290 alone; ref. 5) and create a new nuclear export signal (NES)
motif (13) at the NPM protein COOH terminus. Both abnormalities
act in concert (5) to aberrantly localize NPM leukemic mutants in
cytoplasm, as easily detected by immunohistochemistry (14, 15).
Most of NPM leukemic mutants identified to date (16) lose both
tryptophans 288 and 290, which are involved in NPM nucleolar
localization (17); the others retain tryptophan 288. Six different
mutation-related COOH-terminal NES sequences have been
detected (16). Interestingly, COOH-terminal NES sequences and
patterns of tryptophan loss are not randomly distributed (12). The
L-xxx-V-xx-V-x-L NES motif, the most common in NPM mutants, is
always associated with loss of both tryptophans (12). In contrast,
NES motif variants (where valine at the NES second position is
replaced by leucine, phenylalanine, cysteine, or methionine) are
found only when tryptophan 288 is retained (12). Tryptophans 288
and 290 drive NPM into the nucleolus (17), but when tryptophan 288
is retained, immunohistochemistry shows that NPM mutants still
localize in cytoplasm (14). Therefore, to get mutants out of the
nucleus, the COOH-terminal NES sequence of NPM mutants
retaining tryptophan 288 has to counterbalance the tryptophan
288 driving force to the nucleolus. This raises the question about
whether variant COOH-terminal NES motifs have stronger nuclear
export efficiency than the more common L-xxx-V-xx-V-x-L NES
motif.
To assess whether the COOH-terminal NES motifs of NPM
mutants differ in their nuclear export efficiency, we studied
subcellular expression of different mutants at various concentra-
tions of leptomycin B, a specific inhibitor of Exportin/Crm1 receptor
(18, 19), and used a Rev(1.4)-eGFP fusion protein–based functional
nuclear export assay (20) to measure the nuclear export activity of
each COOH-terminal NES sequence after isolation from mutated
NPM proteins (16). Seeking a functional explanation of nucleolus-
restricted expression of wild-type NPM, we also used the same
shuttling assay to assess the nuclear export strength of the two
physiologic NH2-terminal NES motifs (21, 22) of wild-type NPM.
We found that COOH-terminal NES motifs of NPM mutants vary
greatly in their nuclear export strength, suggesting natural
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selection of most efficient NES motifs in NPM mutants retaining
tryptophan 288. This biological association favors maximum NPM
mutant accumulation in cytoplasm and could be a critical event in
leukemogenesis. Our results also account for the predominant
nucleolar localization of wild-type NPM protein.
Materials and Methods
pEGFP-C1-NPM plasmid constructs. pEGFP-C1-NPMmA (5) and
pEGFP-C1-NPMmE (12) were used as templates to generate the following
derivative constructs: pEGFP-C1-NPMmA-C288W, in which tryptophan (W)
288, acting as a partial nucleolar localization signal (NoLS), was reinserted
into NPM mutant A; pEGFP-C1-NPMmE-LxxxVxxVxL, in which the NPM
mutant E COOH-terminal NES motif (LxxxLxxVxL) was replaced by the
mutant A NES motif (LxxxVxxVxL); and pEGFP-C1-NPMmE-W288C, in
which W288 in mutant E was replaced by a cysteine (C). Plasmids were
generated with the QuikChange Site-Directed Mutagenesis Kit (Stratagene),
following the manufacturer’s instructions, with primers designed on the
following sequences: pEGFP-C1-NPMmA-C288W, 5 ¶-CTATTCAA-
GATCTCTGGCTGGCAGTGGAGGAAGTCTC; pEGFP-C1-NPMmE-
LxxxVxxVxL, 5¶-GATCTCTGGCAGTCTGTTGCCCAAGTCTCTTTAAG; and
pEGFP-C1-NPMmE-W288C, 5 ¶-GAGGCTATTCAAGATCTCTGT-
CAGTCTCTTGCCC.
Rev(1.4)-eGFP fusion plasmids containing NPM NES motifs. HIV-1
Rev protein shuttles between cytoplasm and nuclear compartments (23).
Nuclear export efficiency of NES motifs from wild-type and mutated NPM
proteins was measured using a Rev(1.4)-eGFP fusion protein–based
functional nuclear export assay (20). The NES-mutated Rev(1.4)-eGFP and
the positive control Rev(1.4)-NES3-eGFP (with the Rev NES reinserted)
fusion plasmids were generated by one of the authors (B.H.) at the Westmead
Institute for Cancer Research, Westmead Hospital (Sydney, Australia).
Double-strand DNA coding for several putative NES motifs from wild-
type NPM (NES 42–49 and NES 94–102) and leukemic mutants at their
COOH termini (LxxxVxxVxL, LxxxLxxVxL, LxxxCxxVxL, LxxxFxxVxL, and
LxxxMxxVxL and mut6; refs. 16, 21, 22) was obtained by annealing partially
complementary synthetic oligonucleotides bearing BamHI-AgeI compatible
ends and ligating into BamHI-AgeI–digested Rev(1.4)-eGFP by standard
procedures. Oligonucleotides are listed below: Rev(1.4)-NES-42–49-eGFP-F,
5¶-GATCCATTATCTTTAAGAACGGTCAGTTTAGGA; Rev(1.4)-NES-42–49-
eGFP-R, 5¶-CCGGTCCTAAACTGACCGTTCTTAAAGATAATG; Rev(1.4)-NES-
94–102-eGFP-F, 5¶-GATCCAATAACACCACCAGTGGTCTTAAGGTTGAAA;
Rev(1 .4 ) -NES-94–102-eGFP-R , 5 ¶-CCGGTTTCAACCTTAAGAC-
CACTGGTGGTGTTATTG; Rev(1.4)-LxxxVxxVxL-eGFP-F, 5¶-GATCCA-
GATCTCTGTCTGGCAGTGGAGGAAGTCTCTTTAAGAAAAAGA; Rev(1.4)-
LxxxVxxVxL-eGFP-R, 5¶-CCGGTCTTTTTCTTAAAGAGACTTCCTCCACTGC-
CAGACAGAGATCTG; Rev(1.4)-LxxxLxxVxL-eGFP-F, 5 ¶-GATCCA-
GATCTCTGGCAGTCTCTTGCCCAAGTCTCTTTAAGAAAAAGA; Rev(1.4)-
LxxxLxxVxL-eGFP-R, 5¶-CCGGTCTTTTTCTTAAAGAGACTTGGGCAAGA-
GACTGCCAGAGATCTG; Rev(1.4)-LxxxCxxVxL-eGFP-F, 5¶-GATCCA-
GATCTCTGGCAGTGCTGCTCCCAAGTCTCTTTAAGAAAAAGA; Rev(1.4)-
LxxxCxxVxL-eGFP-R, 5¶-CCGGTCTTTTTCTTAAAGAGACTTGGGAGCAG-
CACTGCCAGAGATCTG; Rev(1.4)-LxxxFxxVxL-eGFP-F, 5¶-GATCCA-
GATCTCTGGCAGTGCTTCGCCCAAGTCTCTTTAAGAAAAAGA; Rev(1.4)-
LxxxFxxVxL-eGFP-R, 5¶-CCGGTCTTTTTCTTAAAGAGACTTGGGCGAAG-
CACTGCCAGAGATCTG; Rev(1.4)-LxxxMxxVxL-eGFP-F, 5¶-GATCCA-
GATCTCTGGCAGTCCATGGAGGAAGTCTCTTTAAGAAAAAGA; Rev(1.4)-
LxxxMxxVxL-eGFP-R, 5¶-CCGGTCTTTTTCTTAAAGAGACTTCCTCCATG-
GACTGCCAGAGATCTG; Rev(1.4)-Mut6-eGFP-F, 5¶-GATCCAGATCTCTGG-
CAAGATTTCTTAAATCGTCTCTTTAAGAAAATAGTTACA; Rev(1.4)-Mut6-
eGFP-R , 5 ¶-CCGGTGTAACTATTTTCTTAAAGAGACGATTTAA-
GAAATCTTGCCAGAGATCTG.
Cell cultures and transfection procedures. NIH-3T3 murine fibro-
blasts were cultured in DMEM supplemented with 10% bovine calf serum,
1% glutamine, and antibiotics. For transfection purposes, cells were seeded
overnight on glass coverslips and transfected using Lipofectamine 2000
(Invitrogen) following the manufacturer’s instructions. After 24-h incubation,
before any treatment, cells were incubated with 10 Ag/mL cycloheximide
(Merck Biosciences Ltd.) for 30 min. Leptomycin B (Merck Biosciences), a
specific Crm1 inhibitor (19), was added at 20 ng/mL final concentration for
standard assays and at doses ranging from 0.1 to 10 ng/mL for dose finding
experiments (see below), always for 5 h; actinomycin D (Sigma-Aldrich) was
added at 5 ng/mL final concentration for 3 h where indicated.
Immunofluorescence analysis. For immunofluorescence and confocal
microscope studies, transfected and treated cells (see above) grown on glass
coverslips were rinsed in PBS and fixed in 4% paraformaldehyde, pH 7.4
(10 min). Nuclei were counterstained with propidium iodide when
necessary. Confocal analysis was done as previously described (24). Briefly,
images were collected with a Zeiss LSM 510 confocal microscope (Carl
Zeiss) using 488-nm ( for eGFP) and 543-nm ( for propidium iodide) laser
lines for excitation. Acousto-optic tunable filter–controlled tuning of laser
lines, pinhole diameters, and light collection configuration were optimized
to obtain best signal-to-noise ratio and to avoid fluorescence crossover.
LSM 510 software regulated the microscope; images were transferred to an
SGI Octane workstation (Silicon Graphics) for further processing. Slices
were reconstructed three-dimensionally using the shadow technique or
isosurface analysis with Imaris software (Bitplane).
NES scoring system. A cell scoring method evaluated export activity of
each NES inserted in pRev (1.4)-eGFP. Cells were observed with an Olympus
AX70 epifluorescence microscope (Olympus) equipped with a 100/1.4
numerical aperture oil immersion objective and a MNIBA optical filter cube
(excitation, 470–495 nm; dichroic mirror, 505 nm; emission, 510–550 nm). A
minimum of 200 cells for each slide were examined by two ‘‘blinded’’
independent observers. Cells with or without cytoplasmic fluorescence were
counted and their percentage calculated using GraphPad Prism 4 software
(GraphPad Software). Three experiments were done. Data showed good
intertest reproducibility. The same slides were examined with a confocal
microscope according to the above procedure. Confocal slices were
projected on the Z axis using the maximum intensity method with the
Imaris software (Bitplane); images were recorded and further processed with
ImageJ (NIH).
Results
NPM leukemic mutants carrying W288 localize aberrantly in
cytoplasm but still bind nucleoli. We reviewed the sequences of
the 37 NPM1 exon 12 mutations thus far identified (16) and the
corresponding abnormalities at the COOH termini of the predicted
NPM mutant proteins. Protein sequences carrying mutations of
both tryptophans 288 and 290 were found in 23 of 37 (62.2%) of
all NPM mutants and >95% of NPMc+ AML patients. This high
frequency concurs with loss of both tryptophans in NPM1 mutation
A, which alone accounts for f80% of NPMc+ AML cases. All
NPM mutants carrying the most common COOH-terminal NES
motif LxxxVxxVxL lack both tryptophans (Table 1; NES variant 1).
W288 retention, although rarely observed in patients (<5%),
occurred in 14 of 37 (37.8%) of NPM leukemic mutant sequences
(Table 1). All NPMmutants retaining W288 displayed one of the five
rare COOH-terminal NES motifs (Table 1; NES variants 2 to 6).
Because tryptophans 288 and 290 are crucial for targeting NPM
to nucleoli (12, 17), we addressed the issue of whether NPM
leukemic mutants carrying mutations of one (W290) or two (W288
and W290) tryptophans vary in their subnuclear expression
pattern. Confocal microscopy compared the nucleolus-binding
ability of eGFP-tagged NPM mutant A (lacking both W288 and
W290) and eGFP-tagged NPM mutant E (retaining tryptophan 288)
in NIH-3T3 transfected cells. NPM mutant A was detected in
cytoplasm and was relocated in nucleoplasm but not in nucleoli
after Exportin/Crm1 inhibition by leptomycin B (Fig. 1, left).
NPM Leukemic Mutants Have Different Strength NES Motifs
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Mutant E showed aberrant cytoplasmic expression but retained the
ability to bind nucleoli (Fig. 1, middle). Removal of tryptophan 288
(mutant eGFP-NPMmE-W288C) abolished mutant E nucleolar
binding in basal conditions and after leptomycin B incubation
(Fig. 1, right). These findings show that tryptophan 288 drives some
mutated NPM protein to nucleoli.
However, NPM leukemic mutants bearing tryptophan 288
accumulate aberrantly in leukemic cell cytoplasm, as docu-
mented by immunohistologic analysis of bone marrow biopsies
from NPMc+ AML patients. Therefore, targeting of these mutants
to nucleoli needs to be counterbalanced by a more efficient
COOH-terminal NES-induced nuclear export. Consequently, the
question arises about whether NES occurring with tryptophan
288 retention has to be stronger than the LxxxVxxVxL NES motif
that is only found with loss of tryptophans 290 and 288.
Low doses of leptomycin B reveal different sensitivity of
NPM leukemic mutants to Crm1 inhibition. We investigated
whether the COOH-terminal NES motifs of NPM leukemic mutants
carrying one (W290) or two (W288 and W290) mutated
tryptophans vary in functional activity. NIH-3T3 cells were trans-
fected with mutants carrying the NES of interest and incubated with
low doses of leptomycin B to highlight differences in export
efficiency of the different COOH-terminal NPM NES motifs.
Leptomycin B incubation was done in NIH-3T3 cells transfected
with NPM mutant A (containing the LxxxVxxVxL COOH-terminal
NES motif and no tryptophans) or NPM mutant E (containing
the LxxxLxxVxL COOH-terminal NES motif plus tryptophan 288).
At conventional doses of leptomycin B (10–20 ng/mL), all NPM
leukemic mutants completely relocated in the nucleus. We
reasoned that a lower dose could reach a Crm1 inhibition thres-
hold and, if different mutant NES sequences have different nuclear
export efficiency, the NPM mutant nuclear relocation patterns
would differ. Titration experiments showed that, at a dose of
0.5 ng/mL, NPM mutant A was almost completely nuclear (Fig. 2,
top) whereas NPM mutant E still showed marked cytoplasmic
positivity (Fig. 2, middle). As expected, similar numbers of NPM
cytoplasmic positive cells were observed with mutant eGFP-
NPMmE-W288C (Fig. 2, bottom).
These findings show that NPM mutant E is less sensitive to
Crm1 inhibition than NPM mutant A (Fig. 2). They do not prove
that the COOH-terminal NES motif causes this difference because
there are two physiologic NES motifs at the NH2 terminus of NPM
Table 1. NES from NPM leukemic mutants and correlation with tryptophan loss
NES
variant
NES
motif
Frequency of
NES variant in
NPM mutants
[n (%)]
Frequency of
NES variant in
NPMc+ AML patients
(%)
Mutation at both
tryptophans associated
with NES variant
[n (%)]
Retention of tryptophan 288
associated with
NES variant
[n (%)]
1 L-xxx-V-xx-V-x-L 23 of 37 (62.2) >95 23 of 23 (100) 0 of 23 (0)
2 L-xxx-L-xx-V-x-L 6 of 37 (16.2) <1 1 of 6 (16.7) 5 of 6 (83.3)
3 L-xxx-F-xx-V-x-L 3 of 37 (8.1) <1 0 of 3 (0) 3 of 3 (100)
4 L-xxx-M-xx-V-x-L 2 of 37 (5.4) <1 0 of 2 (0) 2 of 2 (100)
5 L-xxx-C-xx-V-x-L 2 of 37 (5.4) <1 0 of 2 (0) 2 of 2 (100)
6 L-WQD-F-LNR-L-F-KK-IV 1 of 37 (2.7) <1 0 of 1 (0) 1 of 1 (100)
NOTE: Sequences were analyzed from seven studies, accounting for 2,879 adults and 107 children AML patients (8–11, 16, 37, 38).
Figure 1. NPM leukemic mutants bearing
W288 dislocate in the cytoplasm but
retain ability to bind nucleoli. Subcellular
localization of eGFP-NPM fusion protein in
transfected NIH-3T3 cells. Left, NPM
mutant A (green ) is completely excluded
from nucleus (red). Middle, NPM mutant E
shows a partial nucleolar positivity due to
presence of tryptophan 288; mutant E is no
longer targeted to nucleoli (right ) after
substitution of W288 with cysteine.
LMB, leptomycin B. Images are
three-dimensional reconstructions of
confocal sections (Zeiss LSM 510 and
Imaris software).
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and because NPM interacts with several nuclear and cytoplasmic
proteins which may interfere with NPM mutant shuttling
properties.
NPM leukemic mutants retaining W288 carry COOH-
terminal NES motifs which are stronger than LxxxVxxVxL. To
investigate the activity of both physiologic (NH2-terminal) and
mutation-induced (COOH-terminal) NES motifs of NPM system-
atically and without interfering factors, we conducted a nuclear
export assay on isolated NPM NES sequences cloned into the
Rev(1.4)-eGFP fusion protein (Fig. 3A). Because this construct
contains a nuclear localization signal but lacks a NES motif, the
recombinant Rev(1.4)-eGFP fusion protein produced in cells
localizes in the nucleus (nucleoplasm and nucleoli). Inserting a
functional NES between Rev(1.4) and eGFP protein restores
shuttling activity, which is measured by immunofluorescence
microscope analysis. This construct formed the basis of a func-
tional shuttling assay designed to investigate the activity of each
different NPM COOH-terminal NES motif. Actinomycin D, a RNA
polymerase inhibitor, was used as an enhancer for detecting weak
NES sequences because it increases nucleoplasmic availability of
some nucleolar proteins (20, 25).
Rev(1.4)-eGFP fusion protein showed nuclear localization in
100% of transfected cells, even in the presence of actinomycin D
(Fig. 3B). Rev(1.4)-NES3-eGFP protein [with the physiologic NES
motif of Rev reinserted between Rev(1.4) and eGFP] was
cytoplasmic in most cells, even in basal conditions (Fig. 3B
and C).
The NH2-terminal NES motifs of NPM wild-type protein [i.e.,
amino acids 42–49 (21) and amino acids 94–102 (22)] displayed
weak nuclear export efficiency. When transfected in NIH-3T3
cells, plasmids pRev(1.4)-NES-42–49 and pRev(1.4)-NES-94–102
encoded for fusion proteins which remained in the nucleus in
most cells, both in basal conditions and after actinomycin D
(Fig. 3B and C). The low nuclear export rate of these physiologic
NES of NPM wild-type protein, in combination with signals
driving NPM into the nucleoli (COOH-terminal tryptophans),
provides a reasonable explanation for NPM nucleolus-restricted
localization.
Significant functional export differences emerged in the six
mutated NPM COOH-terminal NES motifs we investigated.
Fusion proteins containing the most common NES motif
LxxxVxxVxL (Rev-LxxxVxxVxL-eGFP) were nuclear in most
transfected cells in basal conditions and produced cytoplasmic
staining on actinomycin D incubation in f40% of transfected
cells (Fig. 3B and C). These findings indicate that NPM COOH-
terminal LxxxVxxVxL is a functional NES motif with intrinsically
weak activity. Therefore, NPM mutant A cytoplasmic localization
depends on accumulated weak activity by the physiologic NES at
the NH2 terminus and the additional NES at the COOH
terminus.
All NES motifs of NPM leukemic mutants retaining W288
produced a clear cytoplasmic staining in most transfected cells in
basal conditions (Fig. 3B and C) and after actinomycin D
incubation, indicating that these NES sequences exert stronger
nuclear export efficiency than the LxxxVxxVxL NES. Leptomycin B
incubation relocated all Rev(1.4)-NPM-NES-eGFP fusion proteins
into the nucleus, confirming that protein export is NES dependent
and Crm1 mediated (not shown).
These results show that NPM COOH-terminal LxxxVxxVxL is a
functional NES motif with rather weak activity and that NPM
leukemic mutants retaining W288 carry COOH-terminal NES
motifs with stronger nuclear export efficiency.
A weak COOH-terminal NES motif and retention of
tryptophan 288 is an unlikely combination. NPM leukemic
mutants carrying a weak COOH-terminal NES motif and a
tryptophan at position 288 have never been detected in primary
AML samples (16). To investigate the consequences of a weak
COOH-terminal NES motif combined with tryptophan 288 retention
on NPM nucleocytoplasmic traffic, we used two artificial NPM
leukemic mutants: (a) mutant A where tryptophan 288 was
reintroduced (eGFP-NPMmA-C288W), and (b) mutant E (which
normally retains W288) where the strong variant LxxxLxxVxL NES
motif was replaced with the common weak LxxxVxxVxL NES (eGFP-
NPMmE-LxxxVxxVxL). On transfection in NIH-3T3 cells, the bulk of
both artificial proteins localized in the nucleoplasm and nucleoli
and displayed greatly reduced cytoplasmic export as compared with
the original NPM leukemic mutants A and E (Fig. 4).
Figure 2. NPM leukemic mutant A is more sensitive to drug-dependent
inhibition of Crm1 than mutant E. Left column, NPM leukemic mutant A (top )
is relocated to the nucleoplasm by 0.5 ng/mL leptomycin B in nearly all
transfected cells; NPM leukemic mutant E (middle ) and artificial mutant
E-W288C (bottom ) are rather unaffected by the same leptomycin B dose. Right
column, histograms show the percentage of transfected cells relocating the
eGFP-NPM fusion proteins from cytoplasm to nucleus after incubation with
increasing doses of leptomycin B.
NPM Leukemic Mutants Have Different Strength NES Motifs
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Figure 3. NPM COOH-terminal NES LxxxVxxVxL is weaker than all other NES motifs. A, schematic image of nucleocytoplasmic traffic in the Rev(1.4)-based
NES efficiency assay, as previously described (20). Different NES test sequences from mutated NPM COOH terminus are challenged against Rev nuclear localization
signal. NES activity is measured in basal state and after incubation with actinomycin D. B, subcellular localization in basal conditions and after actinomycin D (Act D )
incubation is shown for each NPM COOH-terminal NES. The Rev(1.4) plasmid is nuclear by definition, having its own NES sequence inactivated by mutation. The
positive control Rev(1.4)-NES3-eGFP peptide is cytoplasmic in the majority of transfected cells. The NH2-terminal NES motifs of NPM wild-type protein (i.e., amino
acids 42–49 and 94–102) and the NPM COOH-terminal LxxxVxxVxL NES motif drive cytoplasmic localization only in a minority of cells, whereas all other NPM NES
motifs result in cytoplasmic positive staining in a greater proportion of cells. Cytoplasmic positivity of each protein was increased by actinomycin D. Right, columns,
mean obtained from three independent experiments. Nucleus, nucleolar and/or nucleoplasmic eGFP positivity; Cytoplasm, partial or exclusive eGFP cytoplasmic
staining. C, histogram showing different strength of various NPM NES motifs in basal conditions, measured as the percentage of cytoplasmic positive cells (partial
or exclusive eGFP cytoplasmic staining).
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These results indicate that the combination of a weak COOH-
terminal NES motif with tryptophan 288 retention produces
inefficient cytoplasmic accumulation of NPM leukemic mutants.
Because NPM mutants are selected to lose two tryptophans and
acquire a weak additional COOH-terminal NES, or to retain
tryptophan 288 in association with a strong COOH-terminal NES,
the main goal seems to be efficient cytoplasmic export of mutated
NPM protein(s).
Discussion
In this article, we provide evidence for a functional variability
among NES motifs of NPM wild-type protein and those created at
the COOH termini of NPM leukemic mutants, and show that NES-
mediated nuclear export efficiency plays a critical role in
determining nucleolar localization of wild-type NPM and aberrant
cytoplasmic expression of the mutant proteins. The close
relationship between COOH-terminal NES motif strength and
presence of one (W290) or two (W288 and W290) mutated
tryptophans in NPM mutants suggests that COOH-terminal NES
motifs are designed to counterbalance the tryptophan-mediated
force driving NPM leukemic mutants to the nucleolus so as to
achieve maximum cytoplasmic accumulation, which is probably a
critical event in leukemogenesis.
Functional leucine-rich NES sequences commonly provide the
signal for driving a protein out of the nucleus (26). NES motifs
display a high natural variability in export activity (20, 27), which
is probably related to differences in Crm1 affinity. The nuclear
export efficiency of a NES motif represents a critical factor in
intracellular localization of any shuttling protein. Others include
the nuclear import rate, protein-protein (28, 29) or protein-
nucleic acid interactions which lead to retention in cytoplasm or
nucleus.
To assess how the balance between import and export signals
dictates the restricted nucleolar distribution of the NPM wild-type
protein (7), we used a Rev(1.4)-based shuttling assay (20) that gave
us the possibility to quantify the efficiency of each of the two
physiologic NES motifs of wild-type NPM [residues 94–102 (22) and
residues 42–49 (21)] in a cellular system without confounding
factors (e.g., other NES motifs in the same protein or changes in
subcellular localization due to interactions with other proteins).
Using this functional assay, we found that the two NES of NPMwild
type exert weak nuclear export efficiency. This finding suggests that
these NES cannot counterbalance the strength of the bipartite
nuclear localization signal in the mid portion of NPM, which is
responsible for nuclear import (30), and the force of the COOH-
terminal tryptophans, which targets NPM to nucleolus (17, 30).
Consequently, NPM wild type predominantly localizes in the
nucleolus (Fig. 5, left). Although phosphorylation at threonine 95
(which physiologically regulates NPM NES 94–102 activity; ref. 22)
probably does not occur in our artificial Rev(1.4)-based functional
assay, our results support the theory of NES motif weakness (31)
and fit with the observation that the least active NES motifs (20)
belong to proteins that have specific nuclear functions, such as the
transcriptional modulators p53 and activating protein-2. Our
results also imply that the NES signal(s) needs to reach threshold
activity for efficient protein export to cytoplasm.
In NPMc+ AML, an additional NES motif at the COOH terminus
of NPM acting in concert with mutated tryptophans mediates
aberrant cytoplasmic expression of NPM leukemic mutants (12).
Here, we show that functional differences among the COOH-
terminal NES motifs dictate NPM mutant nuclear export. NPM
mutant COOH-terminal NES motifs retaining W288 exhibit
stronger nuclear export activity than the NES motif L-xxx-V-xx-V-
x-L, which is associated with mutations of both tryptophans 288
and 290. This finding strongly suggests that the COOH-terminal
NES motifs of NPM mutants are naturally selected for efficiency in
counteracting forces that drive NPM to nucleolus (i.e., tryptophans
288 and 290 flanking the core hydrophobic residues in the NES
sequence) so as to achieve maximum mutant accumulation in
cytoplasm (Fig. 5, middle and right ). Under similar assay
conditions, another cancer-associated protein (adenomatous poly-
posis coli tumor suppressor) was shown to contain both weak and
strong NES, and cancer-linked mutations that truncate APC also
underlie its export from nucleus to cytoplasm (32).
Interestingly, no NPM leukemic mutant combining a weak NES
motif (L-xxx-V-xx-V-x-L) with W288 retention has ever been
Figure 4. Artificial NPM leukemic mutants expressing both W288 and a weak
NES localize mostly in the nucleus. Top two rows, NIH-3T3 cells transfected
with NPM leukemic mutants pEGFP-C1-NPMmA and pEGFP-C1-NPMmE show
a high proportion of cells expressing the fusion protein in the cytoplasm, as
expected. Bottom two rows, NIH-3T3 cells transfected with artificial NPM
leukemic mutants pEGFP-C1-NPMmA-C288W and pEGFP-C1-NPMmE-
LxxxVxxVxL show a low proportion of cells expressing the fusion protein in the
cytoplasm, as compared with the derivative proteins eGFP-NPMmA and
eGFP-NPMmE.
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detected in NPMc+ AML patients (16). Artificial NPM mutants
combining these two features (NPMmA-W288C and NPMmE-
LVVL) are not efficiently exported into cytoplasm and accumulate
in nucleoli and nucleoplasm. Added to different strength NES
motifs, these observations point to an NPM mutant selection
process. Mutant accumulation in cytoplasm seems to be a
mandatory consequence of the mutation and possibly a critical
event in leukemogenesis because only mutants that are efficiently
exported into cytoplasm will probably give rise to a leukemic clone.
Thus, NPM leukemic mutants seem to be ‘‘born to be exported.’’
The finding that extremely rare variants of NPM1 mutations
occurring at exons other than exon 12 (33, 34) also result in
additional NES and NPM mutant cytoplasmic dislocation further
supports this view. NPM mutants have been shown to delocalize
wild-type NPM and p14ARF into nucleoplasm and cytoplasm
(12, 35), thus perhaps altering their functions (36). However, how
altered NPM traffic contributes to leukemogenesis still remains an
unsolved question.
Our results provide a rationale basis for immunohistochemical
detection of cytoplasmic NPM being fully predictive of all types of
NPM1 mutations (14, 15). Finally, the findings presented in this
article have a potential therapeutic effect because, if small
molecules are to be designed to interfere with abnormal mutant
traffic, all the complex structural and functional alterations that
occur at the COOH termini of NPM mutants will need to be
considered.
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Figure 5. Opposing forces act to determine subcellular localization of wild-type NPM and NPM leukemic mutants. Wild-type NPM (left) is mainly localized in the
nucleolus because the force (tryptophans 288 and 290; dark arrow ) that drives the protein to the nucleolus overwhelms the scarce nuclear export activity (dotted arrow)
of the two physiologic NES motifs (the mutation-related COOH-terminal NES is absent in NPM wild-type). NPM mutant E (middle ) is delocalized in the cytoplasm
because the residual force (tryptophan 288; dark arrow ) that drives the mutant to the nucleolus is counterbalanced by the new COOH-terminal NES with strong nuclear
export activity (thick white arrow ). NPM mutant A (right ) is delocalized in the cytoplasm because the lack of both tryptophans 288 and 290 abolishes the ability of
the mutant to bind nucleolus (dark arrow ) so that the new COOH-terminal NES motif, in spite of its weakness (thin white arrow ), can cause export of the mutant to the
cytoplasm. Arrows, forces dictating nucleocytoplasmic traffic of NPM. NPM, endogenous nucleophosmin; NPMm, leukemic NPM mutant; W, COOH-terminal
tryptophan; X, mutated tryptophan; NES, COOH-terminal nuclear export signal motif; NPC, nuclear pore complex.
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